SLG
CORT icon

Stanley-Laman Group’s Corcept Therapeutics CORT Stock Holding History

Stanley-Laman Group’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.93M Sell
68,196
-429
-0.6% -$25.9K 0.6% 43
2026
Q1 		$2.77M Buy
68,625
+35,314
+106% +$1.32M 0.34% 110
2025
Q4 		$1.16M Buy
33,311
+8,828
+36% +$693K 0.15% 159
2025
Q3 		$2.03M Buy
+24,483
New +$1.77M 0.29% 126

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Stanley-Laman Group's CORT Position: Q2 2026 in Review

Stanley-Laman Group reduced its Corcept Therapeutics (CORT) stake by 0.63% in Q2 2026, selling an estimated $25.9K and leaving 68,196 shares worth $5.93M. The position accounts for 0.6% of the portfolio, ranked #43.

Stanley-Laman Group first reported a position in CORT in Q3 2025 and has held it in 4 quarters since. 423 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Stanley-Laman Group held 68,196 shares of Corcept Therapeutics worth $5.93M as of Q2 2026.
  • Stanley-Laman Group sold 429 Corcept Therapeutics shares in Q2 2026, an estimated $25.9K.
  • Corcept Therapeutics made up 0.6% of Stanley-Laman Group's portfolio in Q2 2026, its #43 holding.
  • Stanley-Laman Group first reported a position in Corcept Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 423 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Stanley-Laman Group's 13F filing for Q2 2026, filed 5 Aug 2026.